Ophthalmic Drugs Market was valued USD 34 billion in 2022 & it will grow at a CAGR of 8% till 2030 : GreyViews

Ophthalmic Drugs Market Size by Drug Class (Anti-Inflammatory, Anti-Glaucoma, Anti-VEGF Agents, Antiallergy, and Others), By Disease (Glaucoma, Eye Allergy, Eye Infection, Uveitis, Dry Eye, Retinal Disorders, and Others), By Dosage Form (Eye Solutions & Suspensions, Eye Drops, Gels, Capsules and Tablets, and Ointments), Regions, Segmentation, and forecast till 2030.

Pune India, Jan. 06, 2023 (GLOBE NEWSWIRE) — The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and the Middle East and Africa. These are the key regions where the ophthalmic drugs market is operating and is predicted to expand soon. The manufacturers and suppliers involved in the ophthalmic drugs market are present across various countries in the above-mentioned regions.

Get Sample Copy of This Report @ https://greyviews.com/reports/ophthalmic-drugs-market/357/request-sample

The report provides a detailed understanding of the market segments which have been formed by combining different prospects such as the drug class, disease, dosage forms mode of application, and regions. Apart from this, the key driving factors, restraints, potential growth opportunities and market challenges are also discussed in the below paragraphs.
The significant players operating in the global ophthalmic drugs market are Novartis AG, Biomedica, Akorn, Inc., C2 PHARMA, Bausch & Lomb, AdvaCare Pharma, Iskon Remedies, Kraeber GmbH, Berry Global Inc., HANSHIN GROUP, Bormioli Pharma, Nolato AB, Gerresheimer AG, WG Pro-Manufacturing Inc., Aptar Group Inc., Adelphi Healthcare Packaging, Amcor Plc., among others. To achieve a substantial market share in the worldwide ophthalmic drugs market and strengthen their position, manufacturers are pursuing expansion methods such as current developments, mergers and acquisitions, product innovations, collaborations, and partnerships, joint ventures.
Ophthalmic drugs are drugs for the eyes, these are generally available in the form of eye drops. Globally, the ophthalmic drugs market is fragmented, with a large number of large-scale vendors dominating the market. Key players are investing heavily in comprehensive R&D activities to increase their market share. There are some factors which are hampering the market growth such as a lack of awareness and rising cataract cases. Many developed nations have a blindness prevalence of less than 0.5 %, and occasionally much lower, while many developing nations have a blindness prevalence of 1 to 2 %. As many as six times as many people suffer from poor vision, which can severely hamper market growth. Moreover, advanced technology is expected to boost market growth by improving physicochemical stability and bioavailability. Increasing healthcare awareness about preventing eye problems and government initiatives to study and develop new ophthalmic drug formulations are contributing to the growth of ophthalmic medications. By type of indication, the segment for retinal disease dominated the global ophthalmic drugs market in 2016. This trend is expected to continue over the forecast period due to the ageing population, the prevalence of macular degeneration, and the surge in sales of ophthalmic drugs to treat retinal diseases.

Enquiry Before Buying This Report @  https://greyviews.com/inquiry/357

Scope of Ophthalmic Drugs Market Report:

Report Metric Information
Study Period 2022-2030
Base Year           2022
Forecast Period 2023-2030
Market Share Unit USD Billion
Segments Covered Drug Class, Disease, Dosage form, and Regions.
Regions Covered North America, Europe, Asia-Pacific, South America, and Middle-East and Africa
Major Players  Novartis AG, Biomedica, Akorn, Inc., C2 PHARMA, Bausch & Lomb, AdvaCare Pharma, Iskon Remedies, Kraeber GmbH, Berry Global Inc., HANSHIN GROUP, Bormioli Pharma, Nolato AB, Gerresheimer AG, WG Pro-Manufacturing Inc., Aptar Group Inc., Adelphi Healthcare Packaging, Amcor Plc., among others.

Segmentation Analysis

Anti-VEGF agents are expected to be the fastest-growing segment in 2022. 

The drug class segment is anti-inflammatory, anti-glaucoma, anti-VEGF agents, antiallergy, and others. The anti-VEGF agent segment is expected to witness the highest growth rate during the forecast period. With the increasing occurrence of pest resistance and the resurgence of crops, sustainable solutions such as bioinsecticides are becoming increasingly popular. A significant number of insect pests destroy plants’ growth and damage crops after harvest or while in storage, resulting in crop losses. Therefore, bioinsecticides are in huge demand and hence propelling the market growth.

Retinol disorders are expected to be the fastest-growing segment in 2022. 

The disease segment is glaucoma, eye allergy, eye infection, uveitis, dry eye, retinal disorders, and others. The retinol disorders segment is expected to witness the highest growth rate during the forecast period. According to amplified eye care, there will be over 11 million AMD cases by the year 2050, with 22 million expected by the year 2050. Additionally, cutting-edge pipeline pharmaceuticals and an increase in sales of ophthalmic medications are forecast to support segment demand in the future.

Eye drops are expected to be the fastest-growing segment in 2022. 

The dosage forms segment is eye solutions & suspensions, eye drops, gels, capsules and tablets, and ointments. The eye drops segment is expected to witness the highest growth rate during the forecast period. Several factors influence the growth of the eye drop market, including the expansion of OTC availability of eye drops, patient compliance issues, and the prevalence of eye illnesses. In addition, new product introductions with altered formulations are predicted to meet market demands. Alcon, for instance, released Systane Complete in January 2022, a preservative-free eye drop.

Regional Analysis           

The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the ophthalmic drugs market include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia.

The North American region witnessed a major share. Regional growth is attributed to an increase in eye diseases, as well as an increase in awareness of eye diseases. Additionally, the presence of leading players such as Alcon, Pfizer Inc, and Bausch and Lomb is expected to fuel regional growth, as well as increasing research and development by leading players.

Country Analysis

  • Germany

Germany’s ophthalmic drugs market size was valued at USD 0.25 billion in 2022 and is expected to reach USD 0.60 billion by 2030, at a CAGR of 6.6% from 2023 to 2030.
A number of significant competitors, the rising prevalence of eye infections, technical improvements, and increased R&D in the country all contribute to the expansion of the ophthalmic eye drop market.

  • China

China’s ophthalmic drugs market size was valued at USD 0.46 billion in 2022 and is expected to reach USD 0.92 billion by 2030, at a CAGR of 6.9% from 2023 to 2030.
Market growth in the country is boosted by the launch of new products and medicines and by businesses investing more in research and development.

  • India

India’s ophthalmic drugs market size was valued at USD 0.39 billion in 2022 and is expected to reach USD 0.98 billion by 2030, at a CAGR of 6.3% from 2023 to 2030.
As a result of increased awareness of eye disorders, the region’s strong healthcare infrastructure, and a number of important companies, including Pfizer and Alcon.
Covid-19 Impact
Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries.

Furthermore, the growth of this market is mainly driven owing to the rising cases of eye infection, propelling the growth of the market across the countries.

Buy Now Full Report @ https://greyviews.com/checkout/357/single_user_license

Contact Us

Rocky Shah

GreyViews

Pune India

Phone: (+44) 162-237-1047

Email: [email protected]

Web: https://greyviews.com/

Follow Us: LinkedIn | Twitter

Browse Related Reports:

Hemodynamic Monitoring System Market Size By System (Invasive Monitoring Systems, Minimally Invasive Monitoring Systems, and Non-invasive Monitoring Systems), By End-User (Catheterization Laboratories, Hospitals, and Others), Regions, Segmentation, and Projection till 2030

https://greyviews.com/reports/hemodynamic-monitoring-system-market/372

Dermatology Lasers Market Size By Type (Gem Laser Machine, Gas Laser Machine, and Semiconductor Laser Machine), By Application (Beauty and Skin Diseases), Regions, Segmentation, and Projection till 2030

https://greyviews.com/reports/dermatology-lasers-market/370

Pharmaceutical Glass Packaging Market Size By Product (Bottles, Vials, Cartridges & Syringes, and Ampoules), By Drug Type (Branded, Biologic and Generic), Regions, Segmentation, and Projection till 2030

https://greyviews.com/reports/pharmaceutical-glass-packaging-market/367

Pharmaceuticals Preservative Market Size By Source (Natural Pharmaceuticals Preservative Agents and Synthetic Pharmaceuticals Preservative Agents), By Function (Antioxidants Pharmaceuticals Preservative Agents, Antimicrobial Pharmaceuticals Preservative Agents, and Chelating Pharmaceuticals Preservative Agents), Regions, Segmentation, and Projection till 2030  

https://greyviews.com/reports/pharmaceuticals-preservative-market/361

Ophthalmic Drugs Market Size By Drug Class (Anti-Inflammatory, Anti-Glaucoma, Anti-VEGF Agents, Antiallergy, and Others), By Disease (Glaucoma, Eye Allergy, Eye Infection, Uveitis, Dry Eye, Retinal Disorders, and Others), By Dosage Form (Eye Solutions & Suspensions, Eye Drops, Gels, Capsules and Tablets, and Ointments), Regions, Segmentation, and Projection till 2030        

https://greyviews.com/reports/ophthalmic-drugs-market/357

Neurosurgery Surgical Power Tools Market Size By Tools Type (Drill, Reamer, Saw, and Others), By Power Type (Pneumatic, Electric, and Battery Powered), Regions, Segmentation, and Projection till 2030          

https://greyviews.com/reports/neurosurgery-surgical-power-tools-market/356

Neonatal Phototherapy Devices Market Size By Light Source (Light-emitting diodes (LEDs), Quartz halogen lamps, Gas discharge tubes, and Fluorescent lamps (FL)), By Configuration (Mobile device and Fixed device), By End-User (Hospitals and Neonatal clinics), Regions, Segmentation, and Projection till 2030

https://greyviews.com/reports/neonatal-phototherapy-devices-market/355

Minimally Invasive Cataract Surgery Devices Market Size By Type (Stand-Alone Glaucoma, Phacoemulsification, Glaucoma in Conjunction with Cataract, Femtosecond Laser Surgery and Extracapsular Cataract Extraction Surgery), By End-User (Ophthalmology Clinic, Hospitals, Outpatient Surgery Centre and Others), Regions, Segmentation, and Projection till 2030       

https://greyviews.com/reports/minimally-invasive-cataract-surgery-devices-market/354

Healthcare Cold Chain Logistics Market Size By Type (Vaccines, Biopharmaceuticals, Clinical Trial Materials, and Others), By Services (Transportation, Storage, and Others), Regions, Segmentation, and Projection till 2030        

https://greyviews.com/reports/healthcare-cold-chain-logistics-market/353

Disposable Syringes Market Size By Product (Conventional Syringes and Safety Syringes), By Application (Immunization Injections and Therapeutic Injections), Regions, Segmentation, and Projection till 2030         

https://greyviews.com/reports/disposable-syringes-market/351

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Mango Bunch takes no editorial responsibility for the same.